Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System

NACompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

August 9, 2019

Primary Completion Date

March 22, 2021

Study Completion Date

March 22, 2021

Conditions
Vascular Closure
Interventions
DEVICE

Cross-Seal System

Use of the Cross-Seal system to close the femoral arteriotomy

Trial Locations (20)

10029

Mt Sinai Medical Center, New York

10032

The Trustees of Columbia University in the City of New York, New York

14642

University of Rochester, Rochester

19096

Lankenau Institute for Medical Research, Wynnewood

23502

Sentara Medical Group, Norfolk

32207

River City Clinical Research, Jacksonville

33620

University of South Florida, Tampa

37660

Holston Valley Medical Center, Kingsport

44195

Cleveland Clinic, Cleveland

45220

Good Samaritan Hospital, Cincinnati

52242

University of Iowa Hospital, Iowa City

57108

North Central Heart, Sioux Falls

73112

INTEGRIS Cardiovascular Physicians, Oklahoma City

77030

Texas Heart Institute and Baylor St. Luke's Medical Center, Houston

78756

Cardiothoracic and Vascular Surgeons, Austin

St. David's Heart and Vascular dba Austin heart, Austin

80218

Vascular Institute of the Rockies, Denver

98122

Swedish Medical Center, Seattle

02215

Beth Israel Deaconess Medical Center, Boston

08854

Rutgers, The State University of New Jersey, Piscataway

All Listed Sponsors
lead

Terumo Medical Corporation

INDUSTRY

NCT03756558 - Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System | Biotech Hunter | Biotech Hunter